Inventiva Plans To Start Lanifibranor Combo Study In NASH, Diabetes In 2022

  • Inventiva IVA announced the design of Phase 2a combination trial of lanifibranor in patients with type 2 diabetes (T2D) and non-cirrhotic non-alcoholic steatohepatitis (NASH).
  • The trial will assess lanifibranor combined with Eli Lilly And Co's LLY Jardiance (empagliflozin).
  • The trial's primary efficacy endpoint is a change in Hemoglobin A1c (HbA1c) at the end of the 24-week treatment compared to baseline. 
  • Secondary endpoints include changes in liver enzymes, glycaemic and lipids parameters, inflammatory markers, and body fat composition. 
  • 63 patients with non-cirrhotic NASH and T2D will be randomized into the trial. 
  • The Company plans to initiate the trial in 1H of 2022, with top-line results in 2H of 2023.
  • Related: Fast Track Status Expanded For Inventiva's NASH Treatment.
  • Price Action: IVA shares closed at $15 on Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapGeneralBriefsNon Alcoholic steatohepatitisPhase 2 TrialType 2 Diabetes
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!